Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 03 02 2020
revised: 07 03 2020
accepted: 08 04 2020
pubmed: 24 5 2020
medline: 15 9 2021
entrez: 24 5 2020
Statut: ppublish

Résumé

Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response-targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mutations (HRm) were evaluated: Among 262 patients, 50 (19%) had HRD (15% germline and 4% somatic). Both groups were analyzed together due to lack of difference in their genomic instability and outcome. Median [95% confidence interval (CI)] follow-up was 21.9 (1.4-57.0) months. Median OS and PFS were 15.5 (14.6-19) and 7 (6.1-8.1) months, respectively. Patients with HRD had improved PFS compared with no HRD when treated with first-line (1L) platinum [HR, 0.44 (95% CI: 0.29-0.67); Pathogenic HRm identifies HRD in patients with PDAC with the best outcome when treated with 1L-platinum. Biallelic HRm and core HRm further enriched benefit from 1L-platinum from HRD.

Identifiants

pubmed: 32444418
pii: 1078-0432.CCR-20-0418
doi: 10.1158/1078-0432.CCR-20-0418
pmc: PMC7380542
mid: NIHMS1585312
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3239-3247

Subventions

Organisme : NCI NIH HHS
ID : K08 CA248964
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cancer. 2018 Apr 1;124(7):1374-1382
pubmed: 29338080
J Clin Oncol. 2011 Aug 1;29(22):3008-15
pubmed: 21709188
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
JCO Precis Oncol. 2018;2018:
pubmed: 30051098
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074
pubmed: 29506128
Nat Genet. 2015 Oct;47(10):1168-78
pubmed: 26343385
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Cancer Discov. 2015 Jul;5(7):752-67
pubmed: 26069190
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Genet. 2019 May;51(5):912-919
pubmed: 30988514
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Clin Cancer Res. 2018 Oct 15;24(20):5018-5027
pubmed: 29954777
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
JAMA Oncol. 2019 Jun 13;:
pubmed: 31194225
JCO Precis Oncol. 2018;2018:
pubmed: 30234181
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Cancer Discov. 2013 Jan;3(1):68-81
pubmed: 23103855
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancer Discov. 2018 Sep;8(9):1096-1111
pubmed: 29903880
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Genome Med. 2017 Jan 23;9(1):4
pubmed: 28115009
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Genet Med. 2019 Jan;21(1):213-223
pubmed: 29961768
Cancer Res. 2008 Apr 15;68(8):2581-6
pubmed: 18413725
JAMA Oncol. 2019 Jun 13;:
pubmed: 31194228
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Drug Resist Updat. 2011 Feb;14(1):22-34
pubmed: 21251871
Nat Commun. 2017 Oct 11;8(1):857
pubmed: 29021619
J Clin Oncol. 2020 May 1;38(13):1378-1388
pubmed: 31976786
Cell. 2020 Jul 23;182(2):481-496.e21
pubmed: 32649862

Auteurs

Wungki Park (W)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Parker Institute for Cancer Immunotherapy, San Francisco, California.

Jiapeng Chen (J)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Weill Cornell Medical College, New York, New York.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

Joanne F Chou (JF)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Weill Cornell Medical College, New York, New York.

Anna M Varghese (AM)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Kenneth H Yu (KH)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Winston Wong (W)

Memorial Sloan Kettering Cancer Center, New York, New York.

Marinela Capanu (M)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Weill Cornell Medical College, New York, New York.

Vinod Balachandran (V)

Memorial Sloan Kettering Cancer Center, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Parker Institute for Cancer Immunotherapy, San Francisco, California.
Department of Surgery, Hepatopancreaticobiliary Surgery, Weill Cornell Medical College, New York, New York.

Caitlin A McIntyre (CA)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Hepatopancreaticobiliary Surgery, Weill Cornell Medical College, New York, New York.

Imane El Dika (I)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.

Danny N Khalil (DN)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
Parker Institute for Cancer Immunotherapy, San Francisco, California.

James J Harding (JJ)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.

Nima Ghalehsari (N)

Memorial Sloan Kettering Cancer Center, New York, New York.

Zoe McKinnell (Z)

Memorial Sloan Kettering Cancer Center, New York, New York.

Sree B Chalasani (SB)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.

Vladimir Makarov (V)

Memorial Sloan Kettering Cancer Center, New York, New York.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

Pier Selenica (P)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Weill Cornell Medical College, New York, New York.

Xin Pei (X)

Memorial Sloan Kettering Cancer Center, New York, New York.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

Nicolas Lecomte (N)

Memorial Sloan Kettering Cancer Center, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Weill Cornell Medical College, New York, New York.

David P Kelsen (DP)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Ghassan K Abou-Alfa (GK)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.

Mark E Robson (ME)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Clinical Genetics Service, Weill Cornell Medical College, New York, New York.

Liying Zhang (L)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
Department of Pathology, Weill Cornell Medical College, New York, New York.

Michael F Berger (MF)

Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Nikolaus Schultz (N)

Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Timothy A Chan (TA)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Weill Cornell Medical College, New York, New York.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

Simon N Powell (SN)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Weill Cornell Medical College, New York, New York.

Jorge S Reis-Filho (JS)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Weill Cornell Medical College, New York, New York.

Christine A Iacobuzio-Donahue (CA)

Memorial Sloan Kettering Cancer Center, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Weill Cornell Medical College, New York, New York.

Nadeem Riaz (N)

Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Weill Cornell Medical College, New York, New York.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

Eileen M O'Reilly (EM)

Memorial Sloan Kettering Cancer Center, New York, New York. oreillye@mskcc.org.
Department of Medicine, Gastrointestinal Oncology Service, Weill Cornell Medical College, New York, New York.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH